Comparing the current results to its competitors, Armata Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Armata Pharmaceuticals Inc 's competitors' average revenue growth of 58.29 %, achieved in the same quarter.
Armata Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -36.11 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -36.11 %
Armata Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company faces competition from commercial pharmaceutical and biotechnology firms, academic institutions, government agencies, and private and public research organizations developing treatments for bacterial infections. Many competitors possess greater financial resources, product development capabilities, manufacturing capacity, and marketing expertise. Large pharmaceutical companies have extensive experience in clinical development and regulatory approval processes. Universities and research institutes also engage in antibacterial research, sometimes directly competing with the company. Competition extends to recruiting scientific and clinical development personnel. The company's competitive position depends on its ability to utilize experience in drug discovery, development, and commercialization, secure patent and proprietary protections, obtain regulatory approvals, establish commercial partnerships, and attract and retain qualified personnel.
Publicly Traded Peers of Armata Pharmaceuticals Inc
Vertex Pharmaceuticals Inc Share Performance
+36.57%
One Year
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.
Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.
Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.
Sources:
Armata Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Armata Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
